In addition, increasing diaphragm expression of ABCB10 was also effective at preventing diaphragm dysfunction associated with a DOX treatment protocol designed to mimic standard DOX dosing typically prescribed to breast cancer patients (i.e., multiple cycles administered once every 3 weeks, ~40 mg/m2/cycle). This evidence concerns the gene ABCB10 and breast carcinoma.